ObvioHealth, a global Virtual Research Organization (VRO), today announces the launch of Augmented ePRO, a first-of-its-kind offer in tech-enabled clinical trial service that combines AI-assisted ePRO instruments with a centralized clinical rating platform to deliver more accurate, standardized study outcomes.
Designed to address the subjectivity and variability that are characteristic of ePRO (electronic patient reported outcomes), this multi-pronged tool enables clinical trial participants to record source data—photos, audio, or video—in real time and upload it using the ObvioHealth app. Once the media is uploaded to the platform, each outcome is assessed and scored by a clinician and/or expert rater. Throughout the process, the COACH (Clinical Oversight And Coordination Hub) virtual site team, provides virtual support to both participants and raters, ensuring quality control from start to finish.
Read more about the platform here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.